Sugi Predict

Sugi Predict / Targets / BOD1L1

BOD1L1

Biorientation of chromosomes in cell division protein 1-like 1 · Q8NFC6 · BOD1L1 on Sugi Atlas →

0 patent compounds predicted against BOD1L1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to BOD1L1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
INCB018424 in Patients With Advanced Hematologic Malignancies PHASE2COMPLETED
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 PHASE1/PHASE2COMPLETED
Danazol for Treatment of Cytopenias in Patients With Cirrhosis PHASE2RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma PHASE1WITHDRAWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Breakpoint Analysis of de Novo Apparently Balanced Chromosomal Translocations EARLY_PHASE1COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility nanRECRUITING
Body Awareness and Aerobic Exercise: Telomere Impact nanCOMPLETED
Immunophenotyping and Xist Gene in AML nanUNKNOWN
Post Market Surveillance & Post Market Clinical Follow up, International, Medical Registry to Confirm the Safety and the Performance of the Anecova Intra Uterine Culture Device nanWITHDRAWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
PCM1-JAK2 in Therapy Related Neoplasms nanUNKNOWN
Telomeric Abnormalities in Colorectal Diseases by Fluorescent in Situ Hybridization Technique nanUNKNOWN
Importance of the Microtubule Cytoskeleton in Oocyte Competence nanCOMPLETED
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
Telomeres Length in Israeli Fibrotic ILD Patients nanENROLLING_BY_INVITATION
Cyclin-dependent Kinase Inhibitor 2A (Placental Senescence Marker) on Labor-related Signals nanUNKNOWN
Biocollection in MyeloDysplastic Syndrome (P-MDS) nanRECRUITING
Multi-Dimensional Genomic Dissection of Ring Chromosome 14 Syndrome nanACTIVE_NOT_RECRUITING
Efect of Quinoa and Flaxseed in Cititoxicity and Glicemic Control in Metabolic Syndrome Patients nanUNKNOWN
Prospective Study to Assess Medical Performance of Optical Mapping and Long Read Sequencing in Detecting Numerical and Structural Chromosome Abnormalities nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a BOD1L1 binder may also engage these)

ProteinNameSimilarity
E9Q6J5 — 1.000 E9Q6J5 →
Q6UB99 — 0.995 Q6UB99 →
Q9UKL3 — 0.992 Q9UKL3 →
Q6UB98 — 0.991 Q6UB98 →
Q61464 — 0.990 Q61464 →
Q8BZ32 — 0.990 Q8BZ32 →
Q4V9H5 — 0.990 Q4V9H5 →
Q5F3G6 — 0.989 Q5F3G6 →
Q9WUF3 — 0.989 Q9WUF3 →
A8MW92 — 0.989 A8MW92 →
Q6P9P0 — 0.989 Q6P9P0 →
PHF20 PHD finger protein 20 0.989 landscape →
Q8CCJ9 — 0.989 Q8CCJ9 →
Q4KLH6 — 0.989 Q4KLH6 →
Q6ZQ06 — 0.989 Q6ZQ06 →
Q96T23 — 0.988 Q96T23 →
Q9JIX8 — 0.988 Q9JIX8 →
Q69ZK6 — 0.988 Q69ZK6 →
Q5TB80 — 0.988 Q5TB80 →
Q61687 — 0.987 Q61687 →
P46100 — 0.987 P46100 →
P49342 — 0.987 P49342 →
Q62394 — 0.987 Q62394 →
Q7YQM4 — 0.987 Q7YQM4 →
Q9NPI7 — 0.987 Q9NPI7 →
Q95208 — 0.987 Q95208 →
Q6KCD5 — 0.987 Q6KCD5 →
Q9QX75 — 0.987 Q9QX75 →
Q76FK4 — 0.987 Q76FK4 →
Q3T0A6 — 0.987 Q3T0A6 →